July 11th 2024
Matthew M Davis, MD, MAPP elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Moderna Reports Superiority Against Variants With Investigational Booster
April 19th 2022The company says its first bivalent investigational vaccine, mRNA-1273.211, was efficacious against the Beta, Delta, and Omicron strains. They have identified another bivalent booster, mRNA-1273.214, which the company sees as its leading candidate for a fall 2022 scheduled dosing.
Read More
Did Full FDA Approval of the Pfizer-BioNTech Vaccine Increase COVID-19 Vaccinations?
April 6th 2022After the US Food and Drug Administration (FDA) fully authorized the Pfizer-BioNTech mRNA vaccine, series-completing second doses increased substantially. However, first vaccine doses were actually administered at lower rates after the approval.
Read More
COVID-19 Vaccination During Pregnancy Doesn’t Increase Peripartum Risks
April 4th 2022A pair of new studies in the Journal of the American Medical Association add to growing evidence that COVID-19 vaccines are safe during pregnancy, showing no increased risk for adverse outcomes among women who were vaccinated during pregnancy and their babies.
Read More
NIH Launches Trial Evaluating Second COVID-19 Booster Shots
March 31st 2022One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.
Read More
Pfizer-BioNTech and Moderna mRNA Vaccines Elicit Different Antibody Responses
March 30th 2022The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.
Read More
Booster Doses of mRNA Vaccines Protected Against Severe COVID-19 from Omicron
March 20th 2022Recent booster shots of mRNA vaccines prevented severe infection, hospitalization and death during the Omicron wave of the pandemic, despite a higher rate of breakthrough infections than was seen during the Delta wave, a new study found.
Read More
Oral Nirmatrelvir Highly Effective Against COVID-19 in Phase 2/3 Trial
March 16th 2022Pfizer’s COVID-19 pill Paxlovid, which includes nirmatrelvir and ritonavir, reduced the risk of hospitalization and death by 89% among adults at high risk for severe disease, recently published phase 2/3 trial data show.
Read More